• Mashup Score: 0

    Over 60% of participants achieved the weight-reduction target of 20% or higher and had improved body composition in a phase 3 trial of tirzepatide in overweight/obesity.

    Tweet Tweets with this article
    • ICYMI: 'Staggering' #WeightLoss With #Tirzepatide https://t.co/QciU3Ht5tw via @medscape #Mounjaro "Something we have sought for decades, we have finally been able to achieve" #GIP + #GLP1

  • Mashup Score: 1

    A novel glucagon/GLP-1 receptor agonist conferred nearly 15% weight loss at 46 weeks among people with overweight or obesity without type 2 diabetes, according to an industry press release. In a phase 2 clinical trial, participants with overweight or obesity and no diagnosis of type 2 diabetes were randomly assigned to subcutaneous BI 456906 (Boehringer Ingelheim and Zealand Pharma) or placebo

    Tweet Tweets with this article
    • Adults with obesity lose nearly 15% of body weight with glucagon/GLP-1 receptor agonist #GLP1 #ozempic #wegovy #mounjaro #semaglutide #gip #tirzepatide https://t.co/sF2lrrXeNk